Related Experiment Video
Updated: Sep 25, 2026
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia
Dawn E Colburn1, Deborah A Thomas, Francis J Giles
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Background:
A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted.
Methods:
Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24-h intravenous infusion repeated every 3-4 weeks.
Results:
Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias.
Conclusion:
The study paclitaxel regimen was ineffective in refractory adult ALL.
